Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Different miRNA expression profiles of CRC with or without lymph node metastasis

ABSTRACT: Identifying the exact molecules associated with CRC metastasis may be crucial to understand the process, which might also be translated to the diagnosis and treatment of CRC. In this study, we investigate the association of microRNA expression patterns with the lymph node metastasis of colorectal cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE48074 | GEO | 2013/12/31

SECONDARY ACCESSION(S): PRJNA208852

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Different miRNA expression profiles of CRC with or without lymph node metastasis

Project description:Identifying the exact molecules associated with CRC metastasis may be crucial to understand the process, which might also be translated to the diagnosis and treatment of CRC. In this study, we investigate the association of microRNA expression patterns with the lymph node metastasis of colorectal cancer. To investigate the association of microRNA expression patterns with the lymph node metastasis of colorectal cancer, eight primary colorectal cancer tissues derived from stage II–III colorectal cancer patients with (n = 4) or without (n = 4) lymph node metastasis were collected and the miRNA expression profiles of them were determined using Agilent miRNA microarray. Different miRNA expression profiles were identified in CRC tissues between lymph node metastasis positive and negative group.

2013-12-31 | E-GEOD-48074 | biostudies-arrayexpress

Expression profiles for lymph node metastasis in I-III colorectal cancer

Project description:Lymph node metastasis(LNM) is the most common metastatic pathway of colorectal cancer (CRC), with a rate of 40.5% to 49.7%. Meanwhile, LNM also is one of the most important prognostic risk factor and often predicts a poor clinical outcome. Therefore, it is necessary to identify relevant genes or elucidate potential molecular mechanisms of LNM in order to develop effective prevention and treatment strategies. The aim of this study is to give an insight into the specific signatures and molecular mechanisms of lymph node metastasis in CRC.

2021-05-18 | GSE174519 | GEO

Lymph Node Metastases in Colon Cancer are Polyclonal

Project description:Recent studies have highlighted the role of sub-clones in tumors. Lymph nodes are generally the first location of metastasis for most solid epithelial tumors including Colorectal cancer (CRC). We sought to understand the genetic origin of lymph node metastasis in CRC by evaluating the relationship between CRC tumor sub-clones and lymph nodes.

2017-11-22 | GSE107225 | GEO

microRNA profiles for lymph node metastasis in T1-stage colorectal cancers.

Project description:If we can more accurately predict the likelihood of regional lymph node metastasis (LNM) for endoscopically resected T1-stage colorectal cancers (CRC), the number of unnecessary additional surgeries can be reduced. We aimed of identify miRNA markers that can predict LNM-positive tumors among T1-stage CRCs and we also developed a miRNA classifier set for facilitating the accuracy and applicability.

2015-09-30 | GSE70574 | GEO

Mass spectrometric detection of proteins associated with lymph node metastasis in T1/2 colorectal cancer from FFPE archival specimens

Project description:Surgical resection of colorectal cancers (CRC) that have not invaded beyond the bowel wall (i.e. Stage I) can achieve 5-year patient survival rates exceeding 90%. In the majority of Stage I cases with T1 (submucosal) or T2 (not beyond the muscularis propria) depth of tumour invasion, surgery alone is curative. However, for approximately 10% of resected T1/2 CRC, even though histopathology inspection of the tumour deems it to be restricted to the bowel wall, malignant cells are identified in draining lymph nodes, signifying local metastasis. These patients are classified with Stage IIIA disease and are at greater risk than Stage I patients whose tumours show similar invasive depth, but lack lymph node involvement. To counter the risk of distant malignant dissemination, Stage IIIA patients require more extensive treatment with adjuvant chemotherapy, while Stage I patients do not. In this study we aim to get a better understanding of the underlying biological pathways linked to lymph node metastasis (LNM) using discovery based MS (DIA) and RNASeq as well as IHC and PRM to verify possible protein marker. All of this was done on archival tissue samples (FFPE).

2021-01-14 | PXD020808 | Pride

Transcription profiling of human early stage cervical cancer tumours WITH AND WITHOUT lymph node metastasis, IN ORDER TO predict lymph node metastasis BEFORE treatment.

Project description:Gene expression profiling of early stage cervical cancer tumours with and without lymph node metastasis, in order to predict lymph node metastasis before treatment. Subsequently, comparing gene expression profiles between healthy cervical tissue and early stage cervical cancer tissue. Experiment Overall Design: All patients had clinical FIGO stage IB-IIA cervical cancer, the low-risk group (N) included 19 patients without unfavourable prognostic factors (positive lymph nodes, parametrial invasion, positive margins or a combination of unfavourable prognostic factors); the high risk group (P) consisted of 16 patients with lymph node metastasis, who were treated with adjuvant radiation therapy with or without chemotherapy. Healthy cervical tissue biopsies (H) were collected from 5 non-cervical carcinoma patients who underwent hysterectomy for benign reasons. RNA pooled from all tumour tissue samples was used as reference sample. Log-ratios of five technical replicates were used for normalization.

2008-04-05 | E-GEOD-7410 | biostudies-arrayexpress

Comparison of lymph node negative (N0) and lymph node metastasis (N+) head and neck squamous-cell carcinomas (HNSCC)

Project description:A classifier was build on 82 training samples to differentiate between lymph node negative (N0) and lymph node metastasis (N+) head and neck squamous-cell carcinomas (HNSCC). The 102 predictor genes that resulted from this classifier where then validated against a independent validation set.

2005-01-09 | E-UMCU-11 | biostudies-arrayexpress

Whole-transcriptome analysis in breast cancer with or without lymph node metastasis

Project description:To identify the mRNAs, long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) involved in the pathogenesis of breast cancer, we performed the whole transcriptome sequencing. The whole transcriptome sequencing was performed with three breast cancer tissues with or without lymph node metastasis in each group, respectively. The results showed that 728 mRNAs, 131 lncRNAs, and 144 circRNAs were differentially expressed in lymph node metastasis group and no lymph node metastasis group (fold change≥2, p<0.05). These data indicate that dysregulation of mRNAs, lncRNAs, and circRNAs may contribute to breast cancer progression.

2021-12-31 | GSE163346 | GEO

Project description:Immune system plays a dual role in cancer by either targeting or supporting neoplastic cells at various stages of disease, including metastasis. Yet, the exact immune-related transcriptome profiles of breast cancer cells and their evolution during dissemination remain undiscovered. This study aimed at exploring immune-related transcriptomic landscape of primary tumors and lymph node metastasis of chemotherapy-naïve breast cancer patients.

2021-07-21 | GSE180186 | GEO

Plasma protein signatures associated with lymph node metastasis in colorectal cancer

Project description:Currently, the diagnostic accuracy of Lymph node metastasis in CRC is currently unsatisfactory.In the present study, we assembled two cohorts of patients with or without LNM and evaluated the changed plasma proteomic. We developed a high-performance prediction model, which showed superior diagnostic accuracy for predicting LNM in patients suffering from this lethal malignancy.

2024-10-17 | PXD056886 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data